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Injury to the central nervous system initiates an
uncontrolled inflammatory response that results in
both tissue repair and destruction. Here, we showed
that, in rodents and humans, injury to the spinal cord
triggered surface expression of CD95 ligand (CD95L,
FasL) on peripheral blood myeloid cells. CD95L
stimulation of CD95 on these cells activated phos-
phoinositide 3-kinase (PI3K) and metalloproteinase-
9 (MMP-9) via recruitment and activation of Syk
kinase, ultimately leading to increased migration.
Exclusive CD95L deletion in myeloid cells greatly
decreased the number of neutrophils and macro-
phages infiltrating the injured spinal cord or the in-
flamed peritoneum after thioglycollate injection.
Importantly, deletion of myeloid CD95L, but not of
CD95 on neural cells, led to functional recovery of
spinal injured animals. Our results indicate that
CD95L acts on peripheral myeloid cells to induce
tissue damage. Thus, neutralization of CD95L should
be considered as a means to create a controlled
beneficial inflammatory response.
INTRODUCTION
Accumulating evidence indicates that the once-called death
receptor, CD95 (Fas, APO-1), fulfils a wide range of physiological
nonapoptotic functions in vivo. In the central nervous system
(CNS), CD95 increases branching of developing neurons, axonal
growth of dorsal root ganglion (DRG) cells, migration of malignant
glioma cells, and differentiation of neural stem cells (NSCs) (Cor-
sini et al., 2009; Desbarats et al., 2003; Kleber et al., 2008; Zuliani
et al., 2006). Whereas in DRGs, the CD95L-CD95 system is240 Immunity 32, 240–252, February 26, 2010 ª2010 Elsevier Inc.thought to mediate axonal growth via ERK kinase activation, in
NSCs and malignant glioma cells, CD95 activates the Src-PI3K
pathway (Corsini et al., 2009; Desbarats et al., 2003; Kleber
et al., 2008). In the immune system, activation-induced cell death
(AICD) has been thoroughly described in activated cycling T cells
as a CD95-dependent process (Dhein et al., 1995). However,
further studies have indicated that the CD95L-CD95 system is
also involved in T cell proliferation (Kennedy et al., 1999). Solid
evidence that the CD95 ligand (CD95L, FasL) can also act as
a proinflammatory mediator came from studies where tissue engi-
neered to overexpressCD95L wascolonized by neutrophils (Kang
et al., 1997; Seino et al., 1997). However, the molecular mecha-
nism by which CD95 induces inflammation has remained elusive.
Injury to the spinal cord elicits an inflammatory response within
the firsthoursafter injury that lasts for several weeks. This response
includes endothelial damage, release of proinflammatory media-
tors, changes in vascular permeability, infiltration of peripheral
inflammatory cells, and activation of astrocytes and microglia. Infil-
trating inflammatory cells can, on one hand, promote wound heal-
ing events but, on the other hand, release toxic factors that amplify
tissue damage (Jones and Tuszynski, 2002; Rolls et al., 2009). Yet,
the precisesignals leading to leukocyte infiltrationare still unknown.
Neutralization of CD95L markedly reduces death of neurons
and oligodendrocytes and improves functional recovery of spinal
injured animals (Demjen et al., 2004). These results have been
further confirmed in CD95-deficient mutant mice (lpr) (Casha
et al., 2005; Yoshino et al., 2004) and in rats treated with a
CD95-Fc reagent (Ackeryet al., 2006). However, the actual source
of CD95L and the mechanism by which the CD95L-CD95 system
induces damage following injury has not been addressed yet.
Here, we report that the source of CD95L following spinal cord
injury (SCI) were infiltrating myeloid cells. Stimulation of CD95 on
peripheral myeloid cells increased their migration via activation
of the Syk-PI3K-MMP pathway. In vivo, CD95-induced migration
of myeloid cells was observed in an animal model of SCI and of
thioglycollate-induced peritonitis. Exclusive deletion of CD95L
on myeloid cells reduced death of neurons and oligodendrocytes
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Figure 1. Increased Cell Surface Expression
of CD95L on Mouse and Human Myeloid
Cells after SCI
(A) Time kinetics of infiltrating immune cells into the
injured spinal cord 1 to 14 days after SCI in bone
marrow chimeras from eGFP donor mice and
lethally irradiated WT recipient mice (BMT-eGFP).
(B) Immune cell types present at the lesion site
24 hr after SCI.
(C) Constitutive and SCI-induced expression of
CD95L on peripheral blood neutrophils and mono-
cytes. N, neutrophils; M, monocytes; L, lympho-
cytes; n = 4/group; *p < 0.05; **p < 0.01. Data
are representative of at least three independent
experiments.
(D) Representative histogram of CD95L surface
expression on neutrophils from a spinal cord
(SC)-injured patient (patient d: first and last time
point after injury) or a healthy control.
(E) Quantification of CD95L expression on neutro-
phils from five SC-injured patients relative to rates
in healthy controls. A, admission to the hospital
(2–5 hr postinjury); d, days after injury; Arrow,
Surgery. Data are presented as mean ± SEM;
CD95L expression in patient’s blood is representa-
tive of at least three independent stainings.
Immunity
CD95L Mediates Inflammation via SFK-Syk-PI3Kand improved functional recovery following SCI. Taken together,
our data demonstrate that CD95L-detrimental function following
SCI is due to activation of the innate inflammatory response
rather than to direct apoptosis of CD95-bearing CNS cells.
RESULTS
Injury to the CNS Increases CD95L Surface Expression
on Peripheral Blood Cells in Rodents and Humans
We have previously shown that systemic neutralization of CD95L
improves functional recovery of spinal-injured mice by reducingImmunity 32, 240–252,the number of neurons and oligodendro-
cytes undergoing apoptosis (Demjen
et al., 2004). Yet, the actual source of
CD95L had remained elusive. CD95L is
poorly expressed in the naive adult spinal
cord, and it can be synthesized by resi-
dent spinal cord cells and/or infiltrating
leukocytes. To characterize the different
populations of immune cells recruited to
the injured spinal cord, we generated
eGFP-bone marrow (BM) chimeras by
transferring bone marrow cells from
eGFP donor mice into WT lethally irradi-
ated recipient mice. In these mice, every
immune cell is eGFP+ (Table S1 available
online). Using flow cytometry, we ana-
lyzed the infiltration of immune cells
gating on the GFP+ cells and using de-
fined cell markers for different immune
cell types. Nearly every immune cell infil-
trating the lesion site at 24 hours after
SCI were CD11b+, a marker for myeloidcells (Figures 1A–1B). From these CD11b+ cells, neutrophils
accounted for more than 65% (GR-1+F4/80 or GR-1hi) and
macrophages (CD11b+F4/80+) for 15% (Figure 1B). The propor-
tion of neutrophils rapidly diminished within the first week, when
macrophage numbers increased (Figure 1A). Infiltration of T cells
(CD3+) started after 7 days (Figure 1A). In summary, among
leukocytes, neutrophils and macrophages, cells involved in
the innate inflammatory response are the first to infiltrate the
injured spinal cord. During the period of myeloid infiltration,
amounts of CD95L mRNA and active caspase-3 reached
maximum amounts (Figure S1), suggesting that these cells mightFebruary 26, 2010 ª2010 Elsevier Inc. 241
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CD95L Mediates Inflammation via SFK-Syk-PI3Krepresent a major source of CD95L. Indeed, CD95L expression
at the surface of peripheral blood neutrophils and monocytes
significantly increased 24 hours after SCI (Figure 1C). Most
importantly, increased surface levels of CD95L on peripheral
blood neutrophils were also observed in spinal injured patients
at early time points following injury. CD95L expression returned
to control amounts at 1 week following injury (Figures 1D and 1E
and Table S2). In patient e, who was followed for 17 days after
injury, a second wave of CD95L expression on the surface of
neutrophils was observed in the second week postinjury
(Figure 1E). By contrast, CD95 surface expression on peripheral
blood cells (PBCs) was not changed upon injury to the spinal
cord (Figure S1).
CD95L Induces Activation of PI3K and
Metalloproteinases via Syk Kinase in Myeloid Cells
We next addressed whether CD95L is acting on CD95 expressed
by myeloid cells. The response to exogenously given CD95L was
studied in bone-marrow-derived neutrophils and mature macro-
phages. Induction of apoptosis via CD95 occurs through the
recruitment of the adapter protein Fas-Associated Death
Domain (FADD) to theDeathDomain (DD) of CD95. Thus, we first
examined FADD association with CD95 on primary macro-
phages treated with recombinant CD95L. Yet, whereas CD95L
treatment induced efficient recruitment of FADD to CD95 in the
CD95 apoptosis sensitive thymoma E20 cells, recruitment of
FADD to CD95 could not be detected in stimulated primary
macrophages (Figure S2). Consistently, macrophages are resis-
tant to CD95-induced cell death (Altemeier et al., 2007; Park
et al., 2003; Shimizu et al., 2005). There is increasing evidence
that CD95L is involved in processes other than apoptosis (San-
cho-Martinez and Martin-Villalba, 2009). In malignant glioma
cells, we have recently reported increased migration upon
CD95L stimulation (Kleber et al., 2008). In these cells, the Src
family kinase Yes and the p85 subunit of PI3K are recruited to
CD95 and activated upon CD95L binding. To address whether
PI3K is also involved in our system, AKT phosphorylation upon
CD95L treatment was assessed. Phosphorylation and, thus,
activation of AKT was induced upon CD95L treatment in both
neutrophils and macrophages (Figures 2A and 2B). Moreover,
phosphorylation of Src family kinases (SFKs) also increased
upon CD95 stimulation in primary macrophages (Figure 2B).
With regard to the neutrophil cell population, further biochemical
studies were performed in DMSO-differentiated HL-60 cells
(dHL-60), a human neutrophil-like cell line. As in the case of
primary macrophages, stimulation of CD95 led to increased
phosphorylation of SFKs (Figure S2). Antibodies used to
measure Y416 phosphorylation of SFKs are crossreactive with
the different family members of this kinase. To address the iden-
tity of the involved SFK, we performed depletion experiments by
pulling down the different SFKs with specific antibodies.
Comparison of representative nondepleted samples with the
depleted lysates allows identification of the SFKs that get phos-
phorylated upon CD95 stimulation. Accordingly, depletion
experiments with Lyn antibodies and not with antibodies to other
SFKs significantly reduced the double band visualized with the
phospho-SFK antibody. This double band appears in the range
of 55-53 kDa, which corresponds to the estimated molecular
weight of Lyn (Figure S2 and data not shown).242 Immunity 32, 240–252, February 26, 2010 ª2010 Elsevier Inc.We next addressed the molecular determinants of PI3K and
SFKs activation upon stimulation of CD95 in immune cells. As
the YXXL motif in CD95 was first described to get phosphory-
lated in primary neutrophils upon CD95 stimulation (Daigle
et al., 2002), we decided to investigate potential CD95 interac-
tors with this motif by using an SH2 array (Figure 2C, upper
panel). As shown, CD95, or a CD95-containing multiprotein
complex, could interact with the SH2 domain of the nonreceptor
tyrosine kinase Zap70-Syk (Figure 2C, lower panel). To validate
the results obtained from the protein array, we performed
peptide-binding experiments, in which the corresponding
sequence of CD95 containing the YXXL motif was incubated
with CD95L-stimulated or nonstimulated lysates. In dHL-60
cells, incubation of the phosphorylated CD95 peptide resulted
in increased binding of Syk compared to the nonphosphorylated
CD95 peptide, as well as a scrambled phosphorylated peptide,
which was used as negative control for sequence specificity
(Figure 2D). Treatment with CD95L further enhanced binding of
Syk to the phosphorylated CD95 peptide (Figure 2D). These
results suggest the presence of adapter proteins and/or the
requirement of posttranslational modifications, which cannot
be mimicked by the peptide itself. Binding of Syk to the phos-
phorylated CD95 peptide was also observed in primary macro-
phages (Figure 2E). However, contrary to the results obtained
in dHL-60, we did not observe differences in the binding upon
treatment with CD95L (Figure 2E). These results were confirmed
in CD95L-stimulated primary macrophages in which association
of CD95 with Syk kinase was detected by coimmunoprecipita-
tion studies (Figure 2F). Further, stimulation of CD95 led to
increased phosphorylation of Syk in both dHL-60 and primary
macrophages (Figure 2G and Figure S2). In B-cells, SFKs get
activated by stimulation of the B-cell receptor (BCR), leading to
activation of Syk, which can further activate SFKs by phosphor-
ylation of the activation loop, thus creating a positive feedback
loop between both molecules (Tamir and Cambier, 1998). To
analyze possible similarities between CD95 and the BCR, we first
studied the effect of SFKs on Syk phosphorylation. Inhibition of
SFKs with the specific inhibitor PP2 blocked CD95L-induced
phosphorylation of Syk in dHL-60 and primary macrophages
(Figure S2). Knockdown of Syk in primary macrophages also
abolished CD95-induced phosphorylation of SFKs and AKT
(Figures 2H–2J). Taken together, these results demonstrate
that Syk kinase couples CD95 to PI3K activation in myeloid cells.
CD95L Mediates Migration of Myeloid Cells
via Syk-MMP Activation
We next studied CD95L-CD95-induced migration of neutrophils
and macrophages via an in vitro transmigration assay through
matrigel-coated transwells. Bone-marrow-derived murine
neutrophils and macrophages, as well as dHL-60 cells, were
plated on the coated transwells and stimulated with CD95L. After
3 hours (neutrophils), 4 hours (dHL-60), and 24 hours (macro-
phages), transmigrated cells were determined. Migration of
neutrophils, dHL-60 cells, and macrophages significantly in-
creased upon treatment with CD95L (Figure 3A). In glioblastoma
cells, we have recently reported that CD95 induces migration via
activation of MMPs (Kleber et al., 2008). In myeloid cells, phar-
macological inhibition of MMP-9 and -2 also abolished CD95L-
induced migration (Figure 3B). Importantly, basal migration of
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CD95L Mediates Inflammation via SFK-Syk-PI3Kprimary macrophages was reduced after neutralization of CD95L
and in macrophages deficient in CD95 (lpr) or CD95L (Fasl/)
(Figure 3C). Thus, exogenous and endogenous CD95L increased
macrophage migration via CD95 in vitro. To address the role ofSyk in CD95L-induced migration, we knocked down Syk in
dHL-60 cells and primary macrophages. Reduced expression of
Syk decreased CD95L-induced migration in dHL-60 and macro-
phages (Figure 3D and Figure S2). Accordingly, CD95L-inducedImmunity 32, 240–252, February 26, 2010 ª2010 Elsevier Inc. 243
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Figure 3. The CD95L-CD95 System Signals Migration of Myeloid Cells via Syk-MMP Activation
(A) CD95L-T4 induced migration of primary neutrophils, dHL-60, and primary macrophages.
(B) MMP-2 and 9 inhibitor blocked CD95L-T4 induced migration of neutrophils, dHL-60, and macrophages.
(C) Basal migration of macrophages was reduced by neutralizing antibodies to CD95L (MFL3) or in macrophages derived from lpr or Fasl/ mice.
(D) Syk knockdown reduced CD95L-induced migration of dHL-60 and macrophages.
(E) CD95L pretreatment of macrophages significantly increases adhesion to ICAM-1. All data are representative of at least two independent experiments with at
least three wells per condition. Data are presented as mean ± SEM; *p < 0.05; **p < 0.01.
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CD95L Mediates Inflammation via SFK-Syk-PI3Ktransmigration was comparable to transmigration induced by a
known Syk-dependent promigratory signal, CX3CL-1 (Fractal-
kine; Figure S2). These data demonstrate that CD95L acts on
CD95 of neutrophils and macrophages in order to increase their
migration via SFK-Syk-PI3K-AKT-MMPs.
It is important to note that leukocyte migratory capability is
only the last step in the overall process of cell trafficking, related
to microenvironmental repositioning. Other crucial events are
involved, such as rolling, integrin triggering, arrest, and transen-
dothelial migration (TEM). CD95L-triggered signaling pathway
could potentially influence all these events. To test whether244 Immunity 32, 240–252, February 26, 2010 ª2010 Elsevier Inc.CD95L may behave as a direct integrin agonist or prime to a
subsequent proadhesive signal, we performed a static adhesion
assay on purified ICAM-1. To this end, adhesion of macro-
phages, either untreated or treated with CD95L at the time of
plating or 30 min before, was assessed at 3 min after plating.
At this time, pretreatment with CD95L significantly increased
the number of macrophages adhering to ICAM-1 (Figure 3E).
This data indicates that prior to triggering transmigration,
CD95L primes macrophages to adhesion signals. Unraveling
the signaling events involved in priming will be subject of future
studies.
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Figure 4. CD95L on Peripheral Myeloid Cells Is Involved in Their Recruitment to the Site of Injury In Vivo
(A) Phosphorylation of AKT in peripheral blood cells was assessed by flow cytometry. Injury to the spinal cord increased the percentage of pAKT-positive cells in
WT, but not in Fasl/ mice.
(B) Infiltration of immune cells, especially of neutrophils (CD45:GR-1high), was reduced as compared to their respective controls in the injured spinal cord of Faslf/
f;LysMcre mice and in mice acutely treated with CD95L-neutralizing CD95 trimer (CD95-RB69) after SCI.
(C) Reduced infiltration of macrophages (CD45: CD11b+, F4/80+) in the injured spinal cord of Faslf/f;LysMcre mice 7 days following SCI.
(D) Infiltration of neutrophils into the inflamed peritoneum was reduced in Faslf/f;LysMcre mice and WT mice acutely treated with CD95-RB69 after thioglycollate
injection.
(E and F) Infiltration of macrophages into the inflamed peritoneum was reduced in (E) Faslf/f;LysMcre mice and (F) lprmice. Data are presented as mean ± SEM. *p <
0.05; **p < 0.01.
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CD95L Mediates Inflammation via SFK-Syk-PI3KCD95L on Myeloid Cells Is Involved
in Their Recruitment to the Site of Injury In Vivo
To address if CD95L is also involved in AKT activation in periph-
eral myeloid cells in vivo, we first analyzed the activation status of
AKT after SCI in wild-type (WT) and Fasl/ mice. Injury to the
spinal cord induced AKT phosphorylation in WT, but not
CD95L-deficient PBCs (Figure 4A). To further analyze the role
of CD95L in myeloid cells in vivo, we specifically deleted
CD95L in neutrophils and macrophages (Fasl f/f;LysMcre). Verified
deletion of CD95L in myeloid cells with regard to mRNA and
protein amounts did not influence percentages or absolute
numbers of blood leukocytes in naive or injured animals, the
phagocytic function of neutrophils and monocytes, or CD95
surface expression on peripheral blood cells (PBCs) (Figure S3
and data not shown).
In this mouse line, we analyzed the number of immune cells
(CD45+) present in the spinal cord following transection injury
of the spinal cord. Six and 24 hours, as well as 7 days, after
SCI, the number of infiltrating immune cells present in the injured
spinal cord was assessed by flow cytometry as previously
described (Stirling and Yong, 2008). In Faslf/f;LysMcre mice, a
significant reduction in infiltrating CD45+ cells, largely identified
as neutrophils (CD45: GR-1hi), was observed (Figure 4B).
Reduced infiltration of neutrophils could already be observed 6
hours after injury, long before the onset of apoptosis (Figure 4B).
Infiltrating macrophages (CD45: CD11b+, F4/80+) were also
markedly reduced 7 days after injury in Fasl f/f;LysMcre mice
(Figure 4C). These data indicate that following SCI, CD95L actsin a paracrine and/or autocrine fashion on neutrophils and
macrophages in order to allow their recruitment to the injured
spinal cord. To exclude any possible developmental role of
CD95L in neutrophil maturation that could explain their lower
infiltration rate into the site of injury, we acutely inhibited
CD95L. In previous studies we used neutralizing antibodies to
CD95L (Demjen et al., 2004). However, these antibodies greatly
varied in their ability to neutralize CD95L. Thus, we generated a
stable CD95L-neutralizing CD95 trimer, CD95-RB69. As a control
protein, we also generated a mutated form of the neutralizing
trimer, CD95-(R87S)-RB69, which is unable to bind CD95L
(Figure S4 and Supplemental Information). Treatment with the
CD95L-neutralizing trimer did not influence the phagocytic
function of thioglycollate-elicited neutrophils or monocytes (Fig-
ure S3). Systemic administration of CD95-RB69, but not of the
mutated form, decreased the infiltration of neutrophils into the
lesion site 24 hours after injury (Figure 4B). Thus, CD95L on
myeloid cells triggers their self-recruitment to the lesion site
in vivo.
Is the proinflammatory effect of CD95L restricted to the inflam-
matory response elicited by the injured CNS? To address this
issue, we examined the infiltration of immune cells in an animal
model of peritonitis induced by intraperitoneal injection of thio-
glycollate, an in vivo model of leukocyte migration. At different
time points after thioglycollate injection, infiltrated immune cells
were removed from the peritoneum, and the amount of the
different immune cell populations was assessed. A reduced
infiltration of neutrophils into the peritoneum of Faslf/f;LysMcreImmunity 32, 240–252, February 26, 2010 ª2010 Elsevier Inc. 245
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injection (Figure 4D). Infiltration of neutrophils was significantly
reduced 6 hours after thioglycollate injection in Faslf/f;LysMcre
and CD95-RB69-treated WT animals, compared to their respec-
tive controls (Figure 4D). We further assessed infiltration of
macrophages in the peritoneum 72 hours after thioglycollate
injection. At this time point, Fasl f/f;LysMcre mice showed a lower
amount of infiltrating macrophages compared to control litter-
mates, although the number of resident macrophages was not
changed (Figure 4E). mRNA amounts of various proinflammatory
cytokines were comparable in thioglycollate-elicited cells of
control littermates and Faslf/f;LysMcre mice (Figure S3), indicating
that the migratory effect of CD95L is independent of cytokine
production. In addition, after thioglycollate activation or SCI,
the number of neutrophils undergoing apoptosis was similar in
mice lacking CD95L activity and their respective controls
(Figure S4). Consistent with these results, spontaneous death
of neutrophils from CD95-deficient lpr (lymphoproliferation) or
CD95L-deficient gld (generalized lymphoproliferative disease)
mice did not differ from the rates in WT mice (Fecho and Cohen,
1998), and blocking CD95/CD95L function with specific antago-
nists had no effect on the spontaneous death of neutrophils
(Brown and Savill, 1999). Thus, CD95L activation of the innate
immune response is not due to CD95 induction of promigratory
cytokines or apoptosis. Macrophage recruitment to the inflamed
peritoneum after thioglycollate injection was also assessed in lpr
mice. To this end, we used 6-week-old lpr animals to avoid alter-
ation in myeloid cell extravasation present at older stages. These
sequelae of immune alterations that follow the development of
autoimmunity can mask differences in thioglycollate-elicited
migration (Fecho and Cohen, 1998; Gresham et al., 1991; Low-
rance et al., 1994). In these mice, basal numbers of resident
macrophages were not changed (Figure 4F). However, as previ-
ously observed in Faslf/f;LysMcre, 72 hours following thioglycollate
injection, we could observe a reduced infiltration of macrophages
in lpr mice compared to their WT counterparts (Figure 4F).
CD95L Acts on the Innate Inflammatory Response
to Induce Tissue Damage after SCI
We have demonstrated that CD95L on peripheral myeloid cells is
used to facilitate their recruitment to the site of injury. Yet, what
are the long term consequences of exclusive neutralization of
CD95L-induced inflammation? To address this issue, we exam-
ined the long term clinical outcome and pathology of spinal
injured animals with or without CD95L expression in the immune
cell compartment in general or in the myeloid compartment.
First, we generated bone-marrow-transplanted mice (BMT
mice) from CD95L-deficient (Fasl/) or as a control, from wild-
type (WT) donor mice and lethally irradiated WT recipient mice
(BMT-Fasl/ or BMT-WT mice, respectively) (Figure S5 and
Table S1). Fasl/ mice could not be used as a recipient due to
defects in neuronal development that preclude significant func-
tional recovery following SCI (Demjen et al., 2004; Zuliani et al.,
2006). BMT-Fasl/ mice had 25% of the CD95L mRNA as
compared to BMT-WT mice and exhibited a significantly
reduced caspase-3 activity in spinal cord tissue at the time at
which injury-induced levels are maximal (Figure S5). In BMT-
Fasl/ mice, NeuN and CNPase immunoreactivity at 11 weeks
after injury was higher compared to BMT-WT mice, indicating246 Immunity 32, 240–252, February 26, 2010 ª2010 Elsevier Inc.that neurons and oligodendrocytes are rescued in BMT-Fasl/
mice (Figure S5). These results clearly demonstrate that immune
cells are a major source of CD95L following SCI and that the
absence of CD95L in the immune cell compartment protects
neurons and oligodendrocytes. To assess the long term conse-
quences of CD95L-induced inflammation, BMT-Fasl/ mice
and their respective controls were subjected either to the previ-
ously used dorsal 80% transection or to the clinically more rele-
vant crush injury of the spinal cord. Mice locomotor performance
was assessed once weekly over a 10 to 11 week period in the
swimming test and in the open field using the Basso Mouse
Scale (BMS). Following transection or crush injury of the spinal
cord, BMT-Fasl/ mice exhibited a higher functional recovery
than BMT-WT mice (Figure S5).
Second, we performed SCI in mice with exclusive deletion of
CD95L in neutrophils and macrophages (Faslf/f;LysMcre) and their
control littermates. Importantly, after transection injury, spinal
cord CD95L mRNA was highly reduced in Faslf/f;LysMcre mice
24 hours after injury, further demonstrating that among immune
cells, infiltrating myeloid cells are the major source of CD95L
(Figure 5A). Besides, 3 days after injury, caspase-3 activity in
the spinal cord of Faslf/f;LysMcre mice was lower than in control
littermates, reaching significance at 7 days (Figure 5B). Consis-
tently, 11 weeks after injury, Faslf/f;LysMcre mice had an increased
number of surviving neurons and oligodendrocytes compared to
their respective controls (Figures 5C and 5D). Furthermore, dele-
tion of CD95L in the myeloid compartment allowed for a higher
functional recovery following either crush or transection injury
to the spinal cord in the BMS, as well as in the swimming test
(Figures 5E and 5F). To analyze a possible effect of T cell-derived
CD95L, Faslf/f;LCKcre mice (Table S1) and control littermates un-
derwent crush injury to the spinal cord. Contrary to Faslf/f;LysMcre
mice, SCI-induced neurological deficits were comparable in
Fasl
f/f;LCKcre
and their respective controls (Figure S5). Thus, we
clearly identified neutrophils and macrophages as the major
source of CD95L, inducing death of neurons and oligodendro-
cytes and, therefore, participating in the pathogenesis of SCI.
Characterization of the Inflammatory Environment
after Neutralization of CD95L
In order to characterize the molecular events regulated upon
neutralization of CD95L on myeloid cells, we examined the
gene signature of Faslf/f;LysMcre mice and their littermate counter-
parts in the spinal cord 24 hours after transection injury. Already
at this early time point, regenerative processes including organ-
ogenesis, development, and neurogenesis are switched on in
Faslf/f;LysMcre mice (Figure S6). Similarly, expression of genes
involved in apoptosis was reduced in Faslf/f;LysMcre mice or
CD95-RB69-treated mice as compared to their respective
controls (Figure S6). Beyond this, lack of CD95L in myeloid cells
or neutralization of CD95L in CD95-RB69-treated animals re-
sulted in downregulation of genes involved in the immune
response (Figure S6). The observed downregulation of proin-
flammatory genes was further validated by qRT-PCR (Figure 6A
and data not shown). Importantly, among these downregulated
proinflammatory cytokines, neutralization of IL-6, IL-1, or
CXCL10 is reported to improve functional recovery after SCI
(Akuzawa et al., 2008; Gonzalez et al., 2007; Okada et al.,
2004). Interestingly, 24 hours after SCI, 65.2% of genes were
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Figure 5. Exclusive Deletion of CD95L in
Myeloid Cells Reduces Death of Neurons
and Oligodendrocytes and Improves Func-
tional Recovery after SCI
(A and B) Twenty-four hours after transection-SCI,
Fasl f/f;LysMcre mice exhibited lower amounts (A) of
CD95L mRNA (n = 6/group) and (B) of caspase-3
activity (n = 4/group) compared to control litter-
mates. mRNA amounts were normalized to naive
WT animals.
(C)Ten to elevenweeks aftercrush-SCI,Faslf/f;LysMcre
mice exhibited increased number of NeuN+ cells
(NeuN: a marker for mature neurons) compared to
Faslf/f control littermates (n = 6/group).
(D) White matter sparing was determined by the
distance between the rostral loss and reappear-
ance caudal to the lesion site of the CNPase stain-
ing in the dorsal funiculus of the spinal cord. Ten to
eleven weeks after crush-SCI, Faslf/f;LysMcre mice
exhibited a shorter distance as compared to the
respective controls, indicating increased white
matter sparing (n = 6/group).
(E and F) Following transection-SCI (E) or crush-SCI
(F), functional improvement over time, as assessed
by Koziol test of BMS and swimming score, was
higher in Faslf/f;LysMcre than in Fasl+/f LysMcre and
Fasl f/f control littermates (n = 10–12/group; p <
0.01). R, rostral to the lesion site; L, lesion site; C,
caudal to the lesion site Data are presented as
mean ± SEM. *p < 0.05; **p < 0.01.
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Figure 6. Deletion of CD95L in Myeloid Cells Regulates the Inflammatory Environment following SCI
(A and B) Gene-expression profiling was performed in Fasf/f;LysMcre mice and CD95-RB69-treated mice and their respective controls 24 hr after SCI (n = 3/group).
(A) Validation of microarray data by qRT-PCR: mRNA amounts of CXCL10, IL-1b, IL-6, CCL6, and Stat-3 24 hr after SCI. (n = 4/group; *p < 0.05; **p < 0.01).
(B) 65.2% of genes were commonly regulated on the data set of Faslf/f;LysMcre compared to Faslf/f littermates and CD95-RB69-treated compared to
vehicle-treated mice 24 hr after SCI.
(C) Caspase-3 activity 7 days following SCI in Fasf/f;Nescre and their respective littermate controls, Fasf/f (n=4 to 5/group; *p < 0.05; **p < 0.01).
(D) Assessment of functional recovery after crush injury of the spinal cord of Fasf/f;Nescre and respective littermate controls.
(E) White matter sparing was determined by the distance between the rostral loss and reappearance caudal to the lesion site of the CNPase staining in the dorsal
funiculus of the spinal cord. Fourteen weeks after crush-SCI, this distance did not differ between Fas f/f;Nescre mice and respective controls, indicating that deletion
of CD95 on neural cells does not influence white matter sparing (n = 3 to 4 per group). Data are presented as mean ± SEM. ns, not significant.
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CD95L on myeloid cells (Faslf/f;LysMcre versus Faslf/f littermates)
and the group with pharmacological inhibition of CD95L
(CD95-RB69-treated versus vehicle-treated mice), indicating
that at this time point, the gene signature is due to the exclusive
deletion of CD95L in the immune cell compartment (Figure S6).
Furthermore, we compared the data sets from the following
animals and their respective control counterparts 24 hours
following SCI: Faslf/f;LysMcre, Fasl/, and CD95-RB69-treated
mice (Table S1). In contrast to Faslf/f;LysMcre animals, in the latter
two groups, CD95L from resident spinal cells is also deleted. For
statistically based meta-analysis of combined microarray of our
three microarray data sets, the GeneMeta package from Biocon-
ductor (http://bioconductor.org) was applied (Supplemental
Information). This analysis provides a single estimate of the
degree of differential expression for each gene while simulta-
neously accounting for the detection of differences between248 Immunity 32, 240–252, February 26, 2010 ª2010 Elsevier Inc.each experiment and animal background (Supplemental Infor-
mation). Comparison of these three data sets allowed the detec-
tion of 612 genes that were consistently and significantly differ-
entially regulated in the spinal cord 24 hours after injury
(Figure S6 and Table S3). The identification of a common gene
signature regardless of the site of CD95L inhibition implies that
the initial cause of CD95L-induced damage is the activation of
the innate inflammatory response.
To finally assess the contribution to tissue damage of CD95L-
induced inflammation versus direct CD95L-induced apoptosis,
we examined caspase activity in mice deficient in CD95 in resi-
dent neural cells (Fasf/f;NesCre) and their littermate controls
(Fasf/f). The extent of caspase-3 activity did not differ between
the two groups (Figure 6C and Figure S6). Most importantly,
the functional recovery or loss of CNPase immunoreactivity
following SCI was not influenced by the lack of CD95 in resident
CNS cells (Figures 6D and 6E). These data demonstrate that
Immunity
CD95L Mediates Inflammation via SFK-Syk-PI3KCD95L detrimental function following SCI is due to its influence
on the innate inflammatory response and not to direct CD95-
induced apoptosis of CD95-bearing resident neural spinal cells.
DISCUSSION
Our results reveal a mechanism by which the CD95L-CD95
system on peripheral myeloid cells mediates their recruitment
to the inflammatory site via the SFK-Syk-PI3K-AKT-MMP
pathway. We show that an injury to the CNS increases expres-
sion of CD95L on peripheral myeloid cells in rodents and
humans. This system is also involved in the recruitment of
myeloid cells to the inflamed peritoneum after thioglycollate
injection. Further, we show that neutralization of CD95L reduces
the initial infiltration of inflammatory cells, creating an inflamma-
tory response that facilitates recovery of locomotor function
after SCI. Importantly, lack of CD95 on CNS resident neural cells
did not result in improved functional recovery following SCI, indi-
cating that apoptosis of CD95-bearing cells does not contribute
to the pathophysiology of SCI.
Until the mid-90s, the dogma that apoptosis does not induce
inflammation was strongly anchored in the scientific community.
It was generally believed that CD95L resolves inflammation by
inducing activation-induced cell death (AICD) of T cells (Griffith
et al., 1995, 1996; Nagata, 1999). Along this line, constitutive
expression of CD95L by cells in the eye and testis was thought
to contribute to the immune-privileged status of these organs
(Griffith et al., 1995, 1996). It was further suggested that consti-
tutive CD95L expression by a variety of tumor populations would
lead to immune evasion (Hahne et al., 1996; O’Connell et al.,
1996; Strand et al., 1996). But unexpectedly, most cell types
and tissues genetically engineered to express CD95L undergo
destruction through neutrophils (Allison et al., 1997; Kang
et al., 1997; Seino et al., 1997). This data would indicate a role
for CD95L as a chemoattractant. Alternatively, it is known that
CD95L is quickly removed from the surface of the cell by metal-
loproteinases, and released CD95L in the blood can bind to
CD95 on peripheral myeloid cells and trigger their recruit-
ment—in this case, the engineered tissue. In the case of spinal
cord injury, a yet unknown chemotactic signal induces expres-
sion of CD95L on peripheral myeloid cells, thereby leading to
activation of Syk-PI3K-AKT via CD95. This signal primes cells
for undirected migration, and the chemotactic gradient arising
from the injured spinal cord directs those cells to the site of injury.
Accordingly, we show that CD95L primes macrophages to
ICAM-1-induced adhesion. Thus, the CD95-CD95L interaction
takes place in the periphery and not in the CNS.
Indirect evidence for a similar role of CD95L in autoimmune
disease is given by the fact that the lpr mutation ameliorates
disease signs in mice with experimental autoimmune encephalo-
myelitis and collagen-induced arthritis (Hoang et al., 2004; Ma
et al., 2004; Sabelko et al., 1997). However, the autoimmune
disease resulting from the lpr mutation hampers the study of
inflammation in this strain. Accordingly, though it has been
reported that WT mice exhibit significantly higher thioglycol-
late-elicited neutrophil extravasation than lpr mice at 6 hours
after stimulation, the absolute numbers of thioglycollate-elicited
neutrophils over a period of 48 hours did not differ between WT
and lpr animals (Fecho and Cohen, 1998). The mice used inthis study were on average old enough (gld, 13 weeks and lpr,
17.5 weeks) to be showing signs of autoimmune disease and,
therefore, results being masked by the autoimmune phenotype.
Factors associated with autoimmunity, such as higher amounts
of TGF-b found in lpr mice compared to littermate controls,
lead to alterations in neutrophil extravasation to the inflamed
peritoneum (Gresham et al., 1991; Lowrance et al., 1994).
Here, we show that exclusive deletion of CD95L on myeloid
cells allows a beneficial innate inflammatory response in an
animal model of peritonitis and of spinal cord injury. Accordingly,
proinflammatory cytokines and chemokines, such as IL-1b, IL-6,
CXCL10, and CCL6, were downregulated in the injured spinal
cord of these animals. Thus, the reduced production of inflam-
matory mediators by CD95L-deficient myeloid cells might
contribute to changes in the inflammatory environment. Indeed
CD95 is described to activate signal transduction pathways
leading to the induction of proinflammatory responses (Baud
and Karin, 2001). Ligation of CD95 can induce proinflammatory
cytokines and chemokines in different cell types, such as
endothelial cells, bronchial epithelial cells, human vascular
smooth muscle cells, and astrocytes (Hohlbaum et al., 2002),
which could explain a reduced proinflammatory environment in
Faslf/f;LysMcre mice. Nevertheless, we show that thioglycollate-
elicited neutrophils and macrophages from Faslf/f;LysMcre mice
expressed the same mRNA amounts of proinflammatory cyto-
kines. Moreover, at 6 hours after SCI or 2 hours after thioglycol-
late-induced peritonitis, one of the earliest time points in neutro-
phil infiltration, reduced numbers of neutrophils in Faslf/f;LysMcre
mice could already be detected. Immune cells that infiltrate the
lesion site produce cytokines upon interaction with other
immune cells or with CNS-resident cells. This leads to amplifica-
tion of the chemotactic gradient and, thereby, to further infiltra-
tion of leukocytes to the lesion site. Thus, we believe that
reduced amounts of proinflammatory cytokines are due to
reduced migration and not to deficient induction of cytokines
via CD95. Taken together, CD95 influences myeloid cell migra-
tion and thereby influence the inflammatory environment. By
contrast, a recent study showing full depletion of neutrophils
using an anti-Ly6G/Gr1 antibody prior to SCI reports increased
amounts of several proinflammatory cytokines including IL-6
and a worsened clinical outcome following SCI of depleted
animals (Stirling et al., 2009). It is noteworthy that neutrophils
and macrophages not only contribute to tissue damage but
also to cleaning the injury site, limiting bacterial infection and
promoting wound healing. Accordingly, neutralization of
CD95L led to a reduction without complete abrogation of infil-
trating neutrophils and macrophages. How this residual inflam-
mation exerts its beneficial effects remains the subject of future
studies.
We have previously shown that CD95L triggers invasion in a
glioblastoma model and differentiation of NSCs via SFK-PI3K-
AKT pathway (Corsini et al., 2009; Kleber et al., 2008). But how
does CD95 induce PI3K activation in myeloid cells? In 1996, At-
kinson and colleagues reported a physical interaction between
CD95 and a nonreceptor tyrosine kinase, the Src familiy member
Fyn in T cells (Atkinson et al., 1996). They further described the
presence of a highly conserved tyrosine-containing YXXL motif
located in the DD of CD95 that resembles an immunoreceptor
tyrosine activation motif (ITAM). Six years later, Daigle andImmunity 32, 240–252, February 26, 2010 ª2010 Elsevier Inc. 249
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in primary neutrophils leads to phosphorylation of this motif, thus
serving as docking sites for SH2-domain-containing proteins.
Phosphorylation of the receptor is thought to be driven by
members of the Src family of nonreceptor tyrosine kinases
(SFKs: Src, Fyn, Yes, Lck, Hck, and Lyn) (Atkinson et al., 1996).
Once the YXXL motif is phosphorylated, other SH2-containing
protein kinases or phosphatases could potentially bind and
initiate activation of downstream signaling pathways. Here, we
show that CD95L stimulation of CD95 on myeloid cells activates
Syk, further leading to PI3K-MMP signaling. Accordingly, block-
ing PI3K has been shown to inhibit migration of immune cells (Ali
et al., 2004; Frommhold et al., 2007). However, the role of SFKs
and Syk in leukocyte migration is still a matter of debate (Baruzzi
et al., 2008). SFK- or Syk-deficient macrophages have signifi-
cantly reduced migration in vitro and in vivo, yet, same deficiency
in neutrophils allows migration in vitro and into the inflamed peri-
toneum but impairs migration into the inflamed lung, or cremas-
ter muscle (Baruzzi et al., 2008). These apparently contradictory
results reflect the presence of different ligands in the various
inflammatory scenarios, with some ligands activating non-
ITAM-dependent promigratory signaling pathways, such as G-
coupled protein receptors (GPCR)-driven PI3K-SFK activation.
The different migratory behavior of CD95L-deficient and
Syk-deficient neutrophils suggests that Syk may transduce
pro- and antimigratory signaling pathways (Mo´csai et al., 2002).
Besides, CD95L might activate other promigratory signaling
pathways that have not been addressed yet.
Do neurons and oligodendrocytes die in the injured spinal cord
due to direct CD95-induced death or, rather, to CD95-elicited
inflammation? It has been shown that neutrophils can kill
bystander cells in coculture systems through the CD95L-CD95
system (Brown and Savill, 1999; Serrao et al., 2001). Moreover,
phagocytosis triggers macrophage release of CD95L and,
thus, is able to induce cell death of bystander cells (Brown and
Savill, 1999). In addition, a recent study has demonstrated that
CD95L is directly able to induce death of oligodendrocytes
through both intrinsic and extrinsic pathways of the CD95-medi-
ated apoptotic signaling (Austin and Fehlings, 2008). However,
all these data have been generated by in vitro studies. The fact
that mice with exclusive genetic deletion of CD95 in neural cells
do not show a decreased caspase-3 activity or improved func-
tional recovery following SCI demonstrates that CD95 exerts
its deleterious function by acting on the innate immune re-
sponse. As a consequence, pharmacological interventions
aimed at neutralization of CD95 activity have to act in the
periphery and not, as previously believed, in the spinal cord.
This would have the additional advantage of not interfering
with the recently reported CD95-regenerating signal in the
CNS (Corsini et al., 2009). Beyond this, neutralization of
CD95L-CD95 system emerges as a candidate therapy for inflam-
matory diseases in general.EXPERIMENTAL PROCEDURES
Animals
Fasl/ were described previously (Karray et al., 2004). C57BL/6J mice were
purchased from Charles River Laboratories. Fasl-floxed mice (Karray et al.,
2004) were bred with LysM Cre mice (Jackson Laboratory) and LCK Cre250 Immunity 32, 240–252, February 26, 2010 ª2010 Elsevier Inc.mice (a kind gift from G. Ha¨mmerling). Fas-floxed mice (kind gift from K. Rajew-
sky) were bred with Nestin-Cre mice (kind gift from G. Schu¨tz). Mice that
ubiquitously express an enhanced green fluorescent protein were a kind gift
from B. Arnold. Experimental animals were age-matched and used at 12–
14 weeks of age. Animals used are described in Table S1 online. All animal
experiments were performed in accordance with institutional guidelines of
the German Cancer Research Center and were approved by the Regierung-
spra¨sidium Karlsruhe, Germany.
Thioglycollate-Induced Peritonitis
For thioglycollate-induced peritonitis, 1 ml of 3% thioglycollate broth (Fluka)
was injected i.p. in Fasl f/f;LysMcre+ and Fasl f/f mice or in WT mice acutely treated
with CD95-RB69 or its respective control. In this model, neutrophils are known
to start infiltrating the peritoneum within the first hours, whereas macrophage
infiltration peaks at 72 hr. At the indicated times, mice were sacrificed, blood
samples were collected, and peritoneal cavities were lavaged with 10 ml sterile
Hank’s balanced salt solution (HBSS; Invitrogen) containing 0.25% bovine
serum albumin (Roche). Total cell counts were performed in a Neubauer
hematocytometer (Brand), and differential cell counts were carried out by
flow cytometry. Results are expressed as the absolute number of neutrophils
or macrophages3 105/cavity. For every experiment performed, blood immune
cell populations were analyzed by the appropriate cell markers.
Migration Assay
Migration of bone-marrow-derived neutrophils or macrophages was assessed
in vitro in a two-chamber migration assay. Transwell inserts (3 mm [BD no.
353096] or 8 mm [BD no. 353097] pore size for neutrophils or macrophages,
respectively) were coated with matrigel (50 mg/ml; BD no. 354234). 5 3 105
neutrophils, 13 106 dHL60, or 2 3 105 macrophages were plated in 500 ml
medium onto the upper chamber. Cells were left untreated or treated with
CD95L-T4 (engineered Mus musculus CD95L [Kleber et al., 2008 and Supple-
mental Information]) by adding 10, 20, and 40 ng/ml to the upper chamber. The
number of migrated cells was counted 3 hr for neutrophils, 4 hr for dHL-60, and
24 hr for macrophages after treatment by using a hemocytometer. CD95L-
induced migration of macrophages was analyzed by blocking basal migration
of macrophages by using neutralizing antibodies to CD95L (MFL3, 10 mg; BD
no. 555290) or the appropriate isotype control (IgG, 10 mg; BD no. 554709).
Data of the migration assays are representative of at least four independent
experiments with six technical replicates per condition.
The role of metalloproteinases on neutrophil and macrophage recruitment
was investigated by using selective inhibitors of MMP-2 and -9. Neutrophils,
dHL-60, and macrophages were preincubated with MMP-2 and -9 inhibitors
(50 mM; Calbiochem no. 444251) 30 minutes prior to CD95L-T4 treatment,
and the number of migrated cells was counted at the times indicated
previously.
Spinal Cord Injury
SCI models: transection injury of the spinal cord was performed as previously
described (Demjen et al., 2004). For the crush injury model, forceps were held
on the spinal cord for 15 seconds, resulting in a lateral compression of the
spinal cord (Plemel et al., 2008). Immediately following injury and for an
additional week, mice received antibiotics (Gentamycin, 5 ml/kg of a 0.2 mg/ml
solution) to prevent infection. Postoperative care included housing of the
animals at 27C, food and water ad libitum, and manual evacuation of the
bladders once daily.
Anti-CD95L Treatment
Mice were treated intravenously 5 minutes after SCI or induction of thioglycol-
late-induced peritonitis with 50 mg (solved in 200 ml sterile PBS) of either
a stable CD95L-neutralizing CD95 trimer, CD95-RB69, or a mutated form,
CD95-(R87S)-RB69, which is unable to bind CD95L and serves as a control.
Behavioral Assessment
All behavioral tests were performed by two independent observers in a double-
blind manner weekly for 9–11 weeks after injury. The general locomotor perfor-
mance of the animals was assessed using the Basso Mouse locomotor rating
Scale (BMS) (Basso et al., 2006) and the swimming test, assessed as previ-
ously described (Demjen et al., 2004). For the BMS, animals were additionally
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CD95L Mediates Inflammation via SFK-Syk-PI3Ktested at the first day after injury. Any mouse showing a BMS score over 0.5
at day 1 was excluded from further studies. As littermate controls (Fasl f/f
and Fasl f/+;LysMcre) showed no significant difference in locomotor activity, their
results were pooled in the crush injury model.
Statistical Evaluation
All statistical summaries data, including the sample size and results of statis-
tical evaluations, are listed in Table S4. For behavioral experiments, the overall
improvement in mice compared to the control group was statistically analyzed
by using the Koziol test (Koziol et al., 1981), a nonparametric test appropriate
for longitudinal data, which allows analysis of the combined data over time.
Statistical analyses of all other endpoints were performed by using the stan-
dard unpaired Student t test. No formal test for normality was applied in
view of the small sample sizes when Student’s t test was applied. All data
were presented as mean ± standard error of the mean (SEM). Statistical signif-
icance was reported by the p value of the statistical test procedures and was
assessed as significant (*p < 0.05) strongly significant (**p < 0.01), or highly
significant (***p < 0.001). All statistical analyses were performed with the
program package ADAM from the Biostatistics Unit of the German Cancer
Research Center, DKFZ.SUPPLEMENTAL INFORMATION
The Supplemental Data include Supplemental Experimental Procedures, six
figures, and four tables and can be found with this article online at doi:10.
1016/j.immuni.2010.01.011.
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